| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 81 | 2024 | 3578 | 4.540 |
Why?
|
| Galectin 3 | 24 | 2017 | 138 | 4.260 |
Why?
|
| Adenoma | 47 | 2021 | 716 | 3.000 |
Why?
|
| Colonic Neoplasms | 42 | 2019 | 1390 | 2.790 |
Why?
|
| Early Detection of Cancer | 22 | 2024 | 1258 | 2.610 |
Why?
|
| Mucins | 18 | 2005 | 285 | 2.470 |
Why?
|
| Barrett Esophagus | 13 | 2018 | 569 | 2.460 |
Why?
|
| Colonoscopy | 30 | 2023 | 518 | 2.050 |
Why?
|
| Mass Screening | 16 | 2023 | 1509 | 1.560 |
Why?
|
| Sigmoidoscopy | 13 | 2015 | 47 | 1.370 |
Why?
|
| Esophageal Neoplasms | 16 | 2018 | 3168 | 1.250 |
Why?
|
| Adenocarcinoma | 29 | 2019 | 7789 | 1.160 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 9 | 2009 | 200 | 1.150 |
Why?
|
| Occult Blood | 7 | 2023 | 64 | 1.150 |
Why?
|
| Folic Acid | 11 | 2019 | 349 | 1.090 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 3 | 2011 | 205 | 1.040 |
Why?
|
| Naphthalenes | 2 | 2024 | 83 | 0.990 |
Why?
|
| Aspirin | 15 | 2019 | 455 | 0.980 |
Why?
|
| Adenomatous Polyps | 8 | 2019 | 45 | 0.970 |
Why?
|
| Antigens, Differentiation | 7 | 2002 | 238 | 0.970 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2024 | 1724 | 0.970 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2024 | 13 | 0.970 |
Why?
|
| Colonic Polyps | 13 | 2019 | 209 | 0.930 |
Why?
|
| Gastrointestinal Diseases | 2 | 2020 | 589 | 0.920 |
Why?
|
| Chemoprevention | 7 | 2018 | 241 | 0.880 |
Why?
|
| Esophagus | 3 | 2018 | 553 | 0.860 |
Why?
|
| Pancreatic Neoplasms | 8 | 2024 | 5061 | 0.830 |
Why?
|
| Cyclooxygenase Inhibitors | 5 | 2009 | 177 | 0.820 |
Why?
|
| Bile Acids and Salts | 4 | 2017 | 246 | 0.740 |
Why?
|
| Galactosides | 4 | 2002 | 26 | 0.730 |
Why?
|
| Humans | 194 | 2024 | 261506 | 0.710 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 10 | 2018 | 521 | 0.710 |
Why?
|
| Vitamin D | 8 | 2018 | 261 | 0.710 |
Why?
|
| Lactones | 4 | 2008 | 94 | 0.680 |
Why?
|
| Dietary Supplements | 13 | 2019 | 558 | 0.670 |
Why?
|
| Transcription Factor AP-1 | 3 | 2010 | 246 | 0.670 |
Why?
|
| Cholecalciferol | 5 | 2017 | 46 | 0.660 |
Why?
|
| Sulfones | 4 | 2008 | 143 | 0.660 |
Why?
|
| Gene Expression | 4 | 2016 | 3570 | 0.640 |
Why?
|
| Neoplastic Stem Cells | 2 | 2016 | 1443 | 0.640 |
Why?
|
| Isoenzymes | 4 | 2002 | 614 | 0.620 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2017 | 8873 | 0.600 |
Why?
|
| Health Status | 1 | 2020 | 590 | 0.570 |
Why?
|
| Colon | 13 | 2019 | 670 | 0.550 |
Why?
|
| Biomarkers, Tumor | 14 | 2024 | 10331 | 0.550 |
Why?
|
| Adenomatous Polyposis Coli | 5 | 2010 | 221 | 0.550 |
Why?
|
| Microbiota | 2 | 2020 | 547 | 0.540 |
Why?
|
| Immunologic Tests | 1 | 2015 | 33 | 0.520 |
Why?
|
| Cell Membrane | 3 | 2016 | 850 | 0.520 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2017 | 193 | 0.510 |
Why?
|
| Constipation | 3 | 2015 | 177 | 0.510 |
Why?
|
| Esophagoscopy | 5 | 2018 | 291 | 0.510 |
Why?
|
| Gastroesophageal Reflux | 4 | 2018 | 334 | 0.490 |
Why?
|
| Cyclooxygenase 2 | 6 | 2009 | 483 | 0.480 |
Why?
|
| Feces | 3 | 2023 | 770 | 0.480 |
Why?
|
| Receptors, Calcitriol | 3 | 2023 | 134 | 0.470 |
Why?
|
| Catechin | 2 | 2015 | 32 | 0.470 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2016 | 600 | 0.470 |
Why?
|
| Tumor Cells, Cultured | 19 | 2016 | 5395 | 0.470 |
Why?
|
| Signal Transduction | 11 | 2017 | 11965 | 0.460 |
Why?
|
| Cyclin D1 | 3 | 2014 | 576 | 0.440 |
Why?
|
| Enterocolitis, Neutropenic | 2 | 2010 | 19 | 0.430 |
Why?
|
| Mucin 5AC | 2 | 2010 | 75 | 0.430 |
Why?
|
| Cell Line, Tumor | 17 | 2023 | 14551 | 0.420 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 4 | 2002 | 215 | 0.420 |
Why?
|
| Neoplasm Proteins | 7 | 2021 | 3230 | 0.410 |
Why?
|
| Gastrointestinal Hemorrhage | 5 | 1996 | 340 | 0.410 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 5178 | 0.400 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2011 | 60 | 0.400 |
Why?
|
| Lectins | 6 | 2008 | 151 | 0.400 |
Why?
|
| Middle Aged | 84 | 2021 | 86204 | 0.400 |
Why?
|
| Protein Kinase C | 2 | 2010 | 396 | 0.390 |
Why?
|
| Calcium | 6 | 2018 | 1537 | 0.390 |
Why?
|
| Stress, Physiological | 5 | 1996 | 492 | 0.390 |
Why?
|
| Esophagitis | 2 | 2010 | 202 | 0.390 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2017 | 4549 | 0.380 |
Why?
|
| Colitis | 3 | 2019 | 340 | 0.380 |
Why?
|
| Wnt Proteins | 2 | 2011 | 397 | 0.370 |
Why?
|
| Diet | 8 | 2015 | 1440 | 0.370 |
Why?
|
| Aged | 71 | 2021 | 70117 | 0.370 |
Why?
|
| Sucralfate | 4 | 1996 | 10 | 0.360 |
Why?
|
| Biomarkers | 4 | 2021 | 5047 | 0.360 |
Why?
|
| Intestinal Polyps | 2 | 2002 | 72 | 0.360 |
Why?
|
| Calcium, Dietary | 3 | 2014 | 56 | 0.360 |
Why?
|
| Antineoplastic Agents | 8 | 2017 | 14289 | 0.350 |
Why?
|
| Diarrhea | 3 | 2018 | 686 | 0.350 |
Why?
|
| Antibodies, Monoclonal | 5 | 2018 | 4367 | 0.350 |
Why?
|
| Mucin-2 | 6 | 2005 | 62 | 0.350 |
Why?
|
| Male | 92 | 2023 | 123000 | 0.340 |
Why?
|
| Female | 94 | 2024 | 141928 | 0.340 |
Why?
|
| Double-Blind Method | 15 | 2018 | 2588 | 0.330 |
Why?
|
| Apoptosis | 9 | 2021 | 7591 | 0.330 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2009 | 161 | 0.320 |
Why?
|
| ras Proteins | 1 | 2012 | 770 | 0.320 |
Why?
|
| Precancerous Conditions | 5 | 2018 | 1058 | 0.310 |
Why?
|
| Laminin | 2 | 2000 | 194 | 0.310 |
Why?
|
| Epithelial Cells | 5 | 2017 | 1818 | 0.300 |
Why?
|
| Risk | 11 | 2018 | 1972 | 0.300 |
Why?
|
| Intestinal Mucosa | 7 | 2013 | 1081 | 0.290 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2006 | 34 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 13 | 2016 | 2594 | 0.290 |
Why?
|
| Hernia, Hiatal | 1 | 2007 | 63 | 0.290 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2007 | 135 | 0.290 |
Why?
|
| Genes, APC | 3 | 2010 | 70 | 0.290 |
Why?
|
| Cimetidine | 3 | 1996 | 28 | 0.290 |
Why?
|
| beta Catenin | 2 | 2009 | 688 | 0.280 |
Why?
|
| Animals | 40 | 2023 | 59536 | 0.280 |
Why?
|
| Mice | 32 | 2023 | 34495 | 0.280 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 5319 | 0.280 |
Why?
|
| Fractals | 2 | 2023 | 11 | 0.280 |
Why?
|
| Cell Transformation, Neoplastic | 7 | 2007 | 2359 | 0.270 |
Why?
|
| Peptic Ulcer | 1 | 2006 | 140 | 0.270 |
Why?
|
| Gastric Mucosa | 3 | 2000 | 613 | 0.270 |
Why?
|
| Carcinoma | 6 | 2017 | 2578 | 0.270 |
Why?
|
| Metaplasia | 3 | 2018 | 383 | 0.270 |
Why?
|
| Spheroids, Cellular | 2 | 2016 | 222 | 0.270 |
Why?
|
| Mutation | 9 | 2024 | 15179 | 0.270 |
Why?
|
| Mucin-1 | 2 | 2023 | 127 | 0.260 |
Why?
|
| Cholagogues and Choleretics | 1 | 2005 | 33 | 0.260 |
Why?
|
| Cholic Acids | 1 | 2005 | 30 | 0.260 |
Why?
|
| Liver Neoplasms | 10 | 2020 | 4557 | 0.260 |
Why?
|
| Prospective Studies | 12 | 2024 | 12873 | 0.260 |
Why?
|
| Helicobacter pylori | 3 | 2000 | 1295 | 0.250 |
Why?
|
| Transforming Growth Factor beta | 3 | 2014 | 1130 | 0.250 |
Why?
|
| Helicobacter Infections | 3 | 2000 | 1216 | 0.250 |
Why?
|
| Risk Factors | 27 | 2021 | 17523 | 0.240 |
Why?
|
| Mice, Nude | 16 | 2017 | 4307 | 0.240 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 1678 | 0.240 |
Why?
|
| Cardiovascular Diseases | 3 | 2008 | 2195 | 0.240 |
Why?
|
| Calcium Carbonate | 3 | 2018 | 28 | 0.240 |
Why?
|
| Ulcer | 2 | 2019 | 78 | 0.240 |
Why?
|
| Breast Neoplasms | 5 | 2016 | 15694 | 0.240 |
Why?
|
| Cell Proliferation | 9 | 2021 | 7226 | 0.230 |
Why?
|
| Risk Assessment | 12 | 2020 | 6869 | 0.230 |
Why?
|
| Anticarcinogenic Agents | 3 | 2017 | 362 | 0.230 |
Why?
|
| Vitamin B Complex | 2 | 2017 | 51 | 0.230 |
Why?
|
| Blotting, Western | 8 | 2014 | 3536 | 0.230 |
Why?
|
| Sialoglycoproteins | 2 | 1996 | 151 | 0.230 |
Why?
|
| Neoplasm Metastasis | 12 | 2004 | 5112 | 0.230 |
Why?
|
| Lung Neoplasms | 6 | 2024 | 11538 | 0.220 |
Why?
|
| Radiotherapy | 1 | 2010 | 1824 | 0.220 |
Why?
|
| Carbohydrates | 2 | 2004 | 68 | 0.220 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2024 | 436 | 0.220 |
Why?
|
| Sulindac | 1 | 2002 | 51 | 0.220 |
Why?
|
| Incidence | 13 | 2018 | 5673 | 0.210 |
Why?
|
| Up-Regulation | 4 | 2017 | 2450 | 0.210 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 3 | 2012 | 469 | 0.210 |
Why?
|
| Stomach Neoplasms | 5 | 2017 | 2278 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 8 | 2019 | 3981 | 0.210 |
Why?
|
| Cysts | 1 | 2023 | 197 | 0.200 |
Why?
|
| Trans-Activators | 2 | 1998 | 1555 | 0.200 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2007 | 986 | 0.200 |
Why?
|
| Smoking | 5 | 2014 | 2440 | 0.200 |
Why?
|
| Wnt Signaling Pathway | 2 | 2016 | 430 | 0.200 |
Why?
|
| Epitopes | 2 | 2019 | 685 | 0.200 |
Why?
|
| Sulfonamides | 2 | 2000 | 1823 | 0.200 |
Why?
|
| Asialoglycoproteins | 1 | 2000 | 3 | 0.200 |
Why?
|
| Gene Silencing | 2 | 2016 | 837 | 0.200 |
Why?
|
| Fumarates | 2 | 2011 | 30 | 0.190 |
Why?
|
| Aptamers, Nucleotide | 1 | 2021 | 62 | 0.190 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2024 | 323 | 0.190 |
Why?
|
| Immunohistochemistry | 11 | 2009 | 7548 | 0.190 |
Why?
|
| Rectum | 5 | 2019 | 467 | 0.190 |
Why?
|
| Amides | 2 | 2011 | 123 | 0.190 |
Why?
|
| Gastrointestinal Tract | 1 | 2023 | 324 | 0.180 |
Why?
|
| Glycosylation | 5 | 2011 | 213 | 0.180 |
Why?
|
| Research Design | 3 | 2024 | 1544 | 0.180 |
Why?
|
| Proctitis | 2 | 2010 | 18 | 0.180 |
Why?
|
| Intestinal Neoplasms | 2 | 1998 | 189 | 0.180 |
Why?
|
| Lipocalins | 2 | 2010 | 54 | 0.180 |
Why?
|
| Neoplasms | 9 | 2019 | 15193 | 0.180 |
Why?
|
| Acute-Phase Proteins | 2 | 2010 | 79 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 1249 | 0.180 |
Why?
|
| Blood Specimen Collection | 1 | 2020 | 93 | 0.170 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2019 | 17 | 0.170 |
Why?
|
| United States | 13 | 2022 | 15433 | 0.170 |
Why?
|
| Transfection | 6 | 2014 | 2944 | 0.170 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2017 | 363 | 0.170 |
Why?
|
| Cell Adhesion | 9 | 2008 | 1008 | 0.170 |
Why?
|
| Prognosis | 10 | 2020 | 21713 | 0.170 |
Why?
|
| Phosphorylation | 6 | 2009 | 4804 | 0.170 |
Why?
|
| Chemokines | 1 | 2020 | 314 | 0.170 |
Why?
|
| Dependovirus | 1 | 2019 | 135 | 0.170 |
Why?
|
| Transduction, Genetic | 1 | 2019 | 475 | 0.160 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 2 | 2016 | 17 | 0.160 |
Why?
|
| Gastrointestinal Agents | 1 | 2019 | 108 | 0.160 |
Why?
|
| RNA, Messenger | 6 | 2009 | 6150 | 0.160 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 334 | 0.160 |
Why?
|
| Thrombosis | 1 | 2005 | 781 | 0.160 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 1999 | 229 | 0.160 |
Why?
|
| Cholangiocarcinoma | 1 | 2023 | 493 | 0.160 |
Why?
|
| Protein Binding | 4 | 2012 | 3438 | 0.160 |
Why?
|
| Gastric Mucins | 1 | 1997 | 12 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2023 | 574 | 0.160 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2019 | 164 | 0.150 |
Why?
|
| Phosphoproteins | 2 | 2017 | 1152 | 0.150 |
Why?
|
| E-Selectin | 4 | 1999 | 103 | 0.150 |
Why?
|
| Pancreatic Stellate Cells | 1 | 2017 | 76 | 0.150 |
Why?
|
| CDX2 Transcription Factor | 1 | 2017 | 37 | 0.150 |
Why?
|
| Adult | 29 | 2020 | 77950 | 0.150 |
Why?
|
| Lipoxins | 1 | 2017 | 20 | 0.150 |
Why?
|
| Promoter Regions, Genetic | 3 | 2013 | 3101 | 0.150 |
Why?
|
| Transcription, Genetic | 4 | 2017 | 3154 | 0.150 |
Why?
|
| Integrin beta1 | 1 | 2017 | 126 | 0.150 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 1331 | 0.150 |
Why?
|
| Recombination, Genetic | 1 | 2019 | 613 | 0.150 |
Why?
|
| Extracellular Matrix | 2 | 2019 | 554 | 0.150 |
Why?
|
| Gastroenterologists | 1 | 2017 | 21 | 0.150 |
Why?
|
| Paracrine Communication | 1 | 2017 | 128 | 0.150 |
Why?
|
| Base Pair Mismatch | 2 | 2012 | 78 | 0.150 |
Why?
|
| Heterografts | 2 | 2016 | 733 | 0.150 |
Why?
|
| Dietary Fiber | 3 | 2008 | 123 | 0.150 |
Why?
|
| Algorithms | 3 | 2024 | 3890 | 0.140 |
Why?
|
| Liver Neoplasms, Experimental | 4 | 1998 | 196 | 0.140 |
Why?
|
| Ovarian Neoplasms | 7 | 2024 | 4638 | 0.140 |
Why?
|
| Docosahexaenoic Acids | 1 | 2017 | 79 | 0.140 |
Why?
|
| Gastroenteritis | 1 | 2019 | 300 | 0.140 |
Why?
|
| Phenotype | 6 | 2019 | 6295 | 0.140 |
Why?
|
| Aged, 80 and over | 12 | 2020 | 29902 | 0.140 |
Why?
|
| Gene Targeting | 1 | 1997 | 292 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2014 | 3639 | 0.140 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2023 | 962 | 0.140 |
Why?
|
| Hemorrhoids | 1 | 2015 | 13 | 0.140 |
Why?
|
| Rectal Neoplasms | 3 | 2016 | 1202 | 0.130 |
Why?
|
| Prostaglandins | 1 | 2015 | 77 | 0.130 |
Why?
|
| Anti-Ulcer Agents | 1 | 1996 | 101 | 0.130 |
Why?
|
| Time Factors | 10 | 2020 | 12926 | 0.130 |
Why?
|
| Polymorphism, Genetic | 5 | 2012 | 1450 | 0.130 |
Why?
|
| Follow-Up Studies | 15 | 2019 | 14889 | 0.130 |
Why?
|
| Cytoskeletal Proteins | 1 | 1997 | 492 | 0.130 |
Why?
|
| Polysaccharides | 1 | 1996 | 197 | 0.130 |
Why?
|
| Secondary Prevention | 3 | 2006 | 329 | 0.130 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2018 | 272 | 0.130 |
Why?
|
| NF-kappa B | 3 | 2017 | 1549 | 0.130 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1995 | 70 | 0.130 |
Why?
|
| Population Surveillance | 2 | 2009 | 627 | 0.130 |
Why?
|
| Smad7 Protein | 1 | 2014 | 16 | 0.130 |
Why?
|
| Carcinogenesis | 2 | 2019 | 1026 | 0.130 |
Why?
|
| Phytotherapy | 1 | 2015 | 110 | 0.130 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2014 | 22 | 0.130 |
Why?
|
| Membrane Proteins | 4 | 2019 | 2819 | 0.130 |
Why?
|
| Vitamins | 1 | 2015 | 157 | 0.130 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2014 | 467 | 0.130 |
Why?
|
| Endoscopic Mucosal Resection | 1 | 2016 | 94 | 0.120 |
Why?
|
| Disease Models, Animal | 5 | 2016 | 7222 | 0.120 |
Why?
|
| Peptide Fragments | 3 | 2000 | 1271 | 0.120 |
Why?
|
| DNA Repair | 3 | 2012 | 1872 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2018 | 649 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2016 | 551 | 0.120 |
Why?
|
| Duodenal Neoplasms | 1 | 1995 | 138 | 0.120 |
Why?
|
| Rats | 4 | 2010 | 6086 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2023 | 5437 | 0.120 |
Why?
|
| Natural Language Processing | 1 | 2015 | 119 | 0.120 |
Why?
|
| Ligands | 3 | 2004 | 995 | 0.120 |
Why?
|
| Molecular Sequence Data | 5 | 2004 | 6089 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2002 | 2022 | 0.120 |
Why?
|
| Renin | 2 | 2011 | 92 | 0.120 |
Why?
|
| Cell Movement | 3 | 2019 | 2466 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 4938 | 0.120 |
Why?
|
| Stromal Cells | 1 | 2017 | 825 | 0.120 |
Why?
|
| Primary Prevention | 1 | 1996 | 255 | 0.120 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 1341 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1077 | 0.120 |
Why?
|
| Dendritic Cells | 1 | 2019 | 1085 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2014 | 287 | 0.110 |
Why?
|
| Documentation | 1 | 2015 | 207 | 0.110 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2014 | 268 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 115 | 0.110 |
Why?
|
| Cholestasis | 1 | 1995 | 203 | 0.110 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1995 | 362 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 1375 | 0.110 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 78 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 739 | 0.110 |
Why?
|
| Hypertension | 3 | 2011 | 1503 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2017 | 10035 | 0.110 |
Why?
|
| Creatinine | 1 | 2014 | 531 | 0.110 |
Why?
|
| Dysbiosis | 1 | 2013 | 134 | 0.110 |
Why?
|
| Osteoporosis | 1 | 2014 | 241 | 0.110 |
Why?
|
| DNA-Binding Proteins | 3 | 2014 | 4821 | 0.110 |
Why?
|
| Cytokines | 2 | 2019 | 2809 | 0.100 |
Why?
|
| Cellular Senescence | 1 | 2014 | 382 | 0.100 |
Why?
|
| Luciferases | 2 | 2013 | 445 | 0.100 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2011 | 13 | 0.100 |
Why?
|
| North America | 2 | 2017 | 314 | 0.100 |
Why?
|
| Digestive System Neoplasms | 1 | 2012 | 82 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2013 | 402 | 0.100 |
Why?
|
| Disease Progression | 7 | 2017 | 6682 | 0.100 |
Why?
|
| Genotype | 8 | 2017 | 4109 | 0.100 |
Why?
|
| Endosonography | 2 | 2005 | 536 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 348 | 0.100 |
Why?
|
| Sensitivity and Specificity | 7 | 2018 | 4971 | 0.100 |
Why?
|
| DNA, Complementary | 3 | 2004 | 869 | 0.100 |
Why?
|
| Positron-Emission Tomography | 4 | 2010 | 2173 | 0.100 |
Why?
|
| Endoscopy, Digestive System | 2 | 2019 | 202 | 0.100 |
Why?
|
| Kidney | 1 | 2020 | 2146 | 0.100 |
Why?
|
| Treatment Outcome | 11 | 2019 | 32848 | 0.100 |
Why?
|
| Caspase 8 | 1 | 2011 | 145 | 0.100 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2011 | 142 | 0.100 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2011 | 31 | 0.100 |
Why?
|
| Bile Reflux | 1 | 2010 | 8 | 0.100 |
Why?
|
| Polyps | 1 | 2012 | 74 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 1994 | 577 | 0.100 |
Why?
|
| Basement Membrane | 4 | 1998 | 138 | 0.100 |
Why?
|
| Antisense Elements (Genetics) | 2 | 2002 | 18 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.100 |
Why?
|
| Gastritis | 1 | 1994 | 373 | 0.100 |
Why?
|
| Antihypertensive Agents | 2 | 2011 | 395 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2018 | 2203 | 0.100 |
Why?
|
| Hodgkin Disease | 1 | 2019 | 1429 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2023 | 2326 | 0.100 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 2315 | 0.090 |
Why?
|
| Neoplasm Staging | 7 | 2016 | 13658 | 0.090 |
Why?
|
| Stomach Diseases | 1 | 1991 | 62 | 0.090 |
Why?
|
| Proportional Hazards Models | 4 | 2009 | 4988 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2023 | 2341 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2010 | 2488 | 0.090 |
Why?
|
| Galactans | 1 | 2010 | 4 | 0.090 |
Why?
|
| Galactose Oxidase | 1 | 2010 | 4 | 0.090 |
Why?
|
| Celecoxib | 2 | 2000 | 200 | 0.090 |
Why?
|
| Disaccharides | 1 | 2010 | 31 | 0.090 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2010 | 47 | 0.090 |
Why?
|
| Physician's Role | 1 | 2012 | 238 | 0.090 |
Why?
|
| Colonoscopes | 1 | 2009 | 22 | 0.090 |
Why?
|
| Lymphatic Metastasis | 3 | 2016 | 4844 | 0.090 |
Why?
|
| Chromosome Mapping | 1 | 2013 | 1471 | 0.090 |
Why?
|
| Hepatitis | 1 | 2010 | 93 | 0.090 |
Why?
|
| Mucous Membrane | 1 | 2010 | 271 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 4744 | 0.090 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2011 | 151 | 0.090 |
Why?
|
| Microsatellite Instability | 1 | 2012 | 400 | 0.090 |
Why?
|
| Single-Blind Method | 2 | 2005 | 409 | 0.090 |
Why?
|
| Base Sequence | 4 | 2004 | 4917 | 0.090 |
Why?
|
| Gastroenterology | 1 | 2012 | 195 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 3022 | 0.090 |
Why?
|
| Glycoproteins | 2 | 2008 | 747 | 0.090 |
Why?
|
| Protein Transport | 1 | 2011 | 734 | 0.090 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 437 | 0.090 |
Why?
|
| Critical Illness | 1 | 1994 | 714 | 0.090 |
Why?
|
| DNA Primers | 2 | 2004 | 1399 | 0.090 |
Why?
|
| Epidermal Growth Factor | 1 | 2010 | 423 | 0.090 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2009 | 69 | 0.080 |
Why?
|
| Tea | 1 | 2009 | 43 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 2054 | 0.080 |
Why?
|
| Linear Models | 4 | 2014 | 1085 | 0.080 |
Why?
|
| Amino Acid Sequence | 3 | 2004 | 4233 | 0.080 |
Why?
|
| Plant Lectins | 2 | 1985 | 27 | 0.080 |
Why?
|
| Vomiting | 1 | 2010 | 354 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2009 | 163 | 0.080 |
Why?
|
| Graft vs Host Disease | 2 | 2010 | 2638 | 0.080 |
Why?
|
| Healthcare Disparities | 2 | 2015 | 598 | 0.080 |
Why?
|
| Enzyme Inhibitors | 2 | 2007 | 1879 | 0.080 |
Why?
|
| Recombinant Proteins | 5 | 2004 | 2927 | 0.080 |
Why?
|
| Germ-Line Mutation | 2 | 2012 | 1046 | 0.080 |
Why?
|
| Prostatic Neoplasms | 6 | 2015 | 5767 | 0.080 |
Why?
|
| Nausea | 1 | 2010 | 525 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 3 | 2008 | 1547 | 0.080 |
Why?
|
| United States Department of Agriculture | 1 | 2007 | 9 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 1303 | 0.080 |
Why?
|
| ROC Curve | 3 | 2021 | 1183 | 0.080 |
Why?
|
| Coloring Agents | 1 | 2008 | 234 | 0.080 |
Why?
|
| Life Style | 4 | 2016 | 612 | 0.080 |
Why?
|
| Linkage Disequilibrium | 3 | 2017 | 460 | 0.080 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 907 | 0.080 |
Why?
|
| Neoplasm Transplantation | 6 | 2002 | 1519 | 0.080 |
Why?
|
| Doxorubicin | 2 | 2011 | 3005 | 0.080 |
Why?
|
| Diet, Mediterranean | 1 | 2007 | 14 | 0.080 |
Why?
|
| RNA Interference | 1 | 2012 | 1408 | 0.080 |
Why?
|
| Antacids | 1 | 1987 | 29 | 0.080 |
Why?
|
| Retrospective Studies | 13 | 2019 | 37905 | 0.080 |
Why?
|
| Cadherins | 1 | 2010 | 660 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 726 | 0.080 |
Why?
|
| Galectins | 2 | 2017 | 71 | 0.080 |
Why?
|
| Neoplasm Grading | 3 | 2019 | 1742 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 2027 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 1350 | 0.080 |
Why?
|
| Cytochromes c | 1 | 2007 | 118 | 0.070 |
Why?
|
| Odds Ratio | 4 | 2017 | 2316 | 0.070 |
Why?
|
| CREB-Binding Protein | 1 | 2007 | 86 | 0.070 |
Why?
|
| Lewis X Antigen | 2 | 1997 | 46 | 0.070 |
Why?
|
| Immunotherapy | 2 | 2020 | 3341 | 0.070 |
Why?
|
| Peptic Ulcer Perforation | 1 | 2006 | 14 | 0.070 |
Why?
|
| Israel | 1 | 2006 | 53 | 0.070 |
Why?
|
| Surveys and Questionnaires | 8 | 2014 | 5687 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 2864 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2012 | 795 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 3869 | 0.070 |
Why?
|
| Plasmids | 1 | 2009 | 837 | 0.070 |
Why?
|
| Microarray Analysis | 1 | 2008 | 392 | 0.070 |
Why?
|
| Endothelium | 2 | 1998 | 158 | 0.070 |
Why?
|
| Genes, Reporter | 1 | 2009 | 798 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 259 | 0.070 |
Why?
|
| DNA Methylation | 2 | 2009 | 2669 | 0.070 |
Why?
|
| Blood Proteins | 2 | 2017 | 294 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 1489 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 7551 | 0.070 |
Why?
|
| C-Reactive Protein | 1 | 2009 | 527 | 0.070 |
Why?
|
| Cell Line | 6 | 2005 | 5114 | 0.070 |
Why?
|
| Cytochrome P450 Family 2 | 2 | 2016 | 10 | 0.070 |
Why?
|
| Logistic Models | 6 | 2016 | 3441 | 0.070 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 4298 | 0.070 |
Why?
|
| Dietary Carbohydrates | 1 | 2006 | 134 | 0.070 |
Why?
|
| Esophageal Diseases | 1 | 2006 | 69 | 0.070 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2009 | 589 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2005 | 123 | 0.070 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2005 | 21 | 0.070 |
Why?
|
| Contraindications | 1 | 2005 | 150 | 0.070 |
Why?
|
| Genetic Variation | 4 | 2016 | 2086 | 0.070 |
Why?
|
| Deoxycholic Acid | 1 | 2005 | 24 | 0.070 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2005 | 51 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2005 | 166 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 1990 | 1073 | 0.060 |
Why?
|
| Europe | 1 | 2006 | 649 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2011 | 1467 | 0.060 |
Why?
|
| Haptoglobins | 1 | 2004 | 26 | 0.060 |
Why?
|
| Hemochromatosis | 1 | 2005 | 35 | 0.060 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2005 | 60 | 0.060 |
Why?
|
| Arthritis | 1 | 2005 | 139 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2012 | 5539 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1995 | 1664 | 0.060 |
Why?
|
| Curcumin | 1 | 2005 | 117 | 0.060 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2005 | 102 | 0.060 |
Why?
|
| Cell Communication | 1 | 2007 | 509 | 0.060 |
Why?
|
| Casein Kinases | 2 | 2000 | 7 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 4757 | 0.060 |
Why?
|
| Guideline Adherence | 2 | 2017 | 636 | 0.060 |
Why?
|
| Cell Survival | 3 | 2019 | 3045 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 3203 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2012 | 1423 | 0.060 |
Why?
|
| Hepatic Duct, Common | 1 | 2023 | 16 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2009 | 2074 | 0.060 |
Why?
|
| Cell Nucleus | 1 | 2009 | 1620 | 0.060 |
Why?
|
| Citrus | 1 | 2002 | 7 | 0.060 |
Why?
|
| Clone Cells | 2 | 2002 | 555 | 0.060 |
Why?
|
| Pectins | 1 | 2002 | 10 | 0.060 |
Why?
|
| Feeding Behavior | 2 | 2006 | 808 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2009 | 2084 | 0.060 |
Why?
|
| Cell Division | 4 | 1999 | 2489 | 0.060 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2004 | 362 | 0.050 |
Why?
|
| Semen | 1 | 2023 | 90 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 860 | 0.050 |
Why?
|
| Gene Deletion | 2 | 2005 | 1442 | 0.050 |
Why?
|
| Transplantation, Heterologous | 2 | 1998 | 1082 | 0.050 |
Why?
|
| Poisson Distribution | 2 | 2015 | 91 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2005 | 2508 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 2063 | 0.050 |
Why?
|
| Introns | 1 | 2004 | 432 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 3 | 2016 | 543 | 0.050 |
Why?
|
| B7-H1 Antigen | 2 | 2020 | 1022 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2005 | 639 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2007 | 987 | 0.050 |
Why?
|
| Confidence Intervals | 3 | 2009 | 756 | 0.050 |
Why?
|
| Inflammation | 2 | 2009 | 2522 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 2 | 1996 | 1064 | 0.050 |
Why?
|
| Esophagogastric Junction | 1 | 2005 | 543 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2024 | 666 | 0.050 |
Why?
|
| Camptothecin | 1 | 2004 | 517 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 2403 | 0.050 |
Why?
|
| Haplotypes | 3 | 2010 | 856 | 0.050 |
Why?
|
| Young Adult | 2 | 2020 | 21445 | 0.050 |
Why?
|
| Pyrazoles | 2 | 2000 | 1471 | 0.050 |
Why?
|
| Transcription Factors | 4 | 2017 | 5270 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 4654 | 0.050 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2006 | 519 | 0.050 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 1981 | 18 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2004 | 842 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2019 | 2803 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 4 | 1998 | 2314 | 0.050 |
Why?
|
| Isoelectric Focusing | 1 | 2000 | 49 | 0.050 |
Why?
|
| Microsatellite Repeats | 2 | 2013 | 575 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2008 | 1411 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2005 | 1070 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2015 | 548 | 0.050 |
Why?
|
| Spermatozoa | 1 | 2023 | 315 | 0.050 |
Why?
|
| Models, Biological | 2 | 2007 | 3254 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2005 | 4053 | 0.050 |
Why?
|
| Histoplasmosis | 1 | 1981 | 74 | 0.050 |
Why?
|
| Intensive Care Units | 3 | 1995 | 717 | 0.050 |
Why?
|
| Alternative Splicing | 1 | 2004 | 584 | 0.050 |
Why?
|
| Cross Infection | 2 | 1996 | 544 | 0.050 |
Why?
|
| Cell Fractionation | 1 | 2000 | 68 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2009 | 6207 | 0.050 |
Why?
|
| Global Health | 1 | 2005 | 657 | 0.050 |
Why?
|
| Rats, Inbred F344 | 1 | 2000 | 224 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 1997 | 4849 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2012 | 945 | 0.050 |
Why?
|
| False Negative Reactions | 2 | 2012 | 275 | 0.050 |
Why?
|
| Immunoprecipitation | 2 | 2014 | 591 | 0.050 |
Why?
|
| Exons | 1 | 2004 | 1328 | 0.050 |
Why?
|
| Cell Compartmentation | 1 | 1999 | 76 | 0.050 |
Why?
|
| Mitochondria | 1 | 2007 | 1282 | 0.040 |
Why?
|
| Microbial Collagenase | 3 | 1992 | 17 | 0.040 |
Why?
|
| Lipocalin-2 | 2 | 2010 | 65 | 0.040 |
Why?
|
| Patient Compliance | 2 | 2003 | 667 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2021 | 700 | 0.040 |
Why?
|
| Pancreas | 2 | 2019 | 718 | 0.040 |
Why?
|
| Fluorescence | 1 | 2019 | 195 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2017 | 315 | 0.040 |
Why?
|
| DNA, Antisense | 1 | 1999 | 42 | 0.040 |
Why?
|
| Protein Kinases | 2 | 2000 | 874 | 0.040 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2000 | 214 | 0.040 |
Why?
|
| Fluorouracil | 2 | 2004 | 1944 | 0.040 |
Why?
|
| Pneumonia | 2 | 1996 | 751 | 0.040 |
Why?
|
| Testis | 1 | 2023 | 717 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2021 | 980 | 0.040 |
Why?
|
| Liver | 3 | 1998 | 2961 | 0.040 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1979 | 222 | 0.040 |
Why?
|
| Infliximab | 1 | 2019 | 130 | 0.040 |
Why?
|
| Comorbidity | 1 | 2005 | 2352 | 0.040 |
Why?
|
| Tissue Distribution | 2 | 1998 | 875 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2015 | 1391 | 0.040 |
Why?
|
| Biopsy | 2 | 2015 | 3443 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2008 | 568 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2019 | 250 | 0.040 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1998 | 123 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 852 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 4892 | 0.040 |
Why?
|
| ral GTP-Binding Proteins | 1 | 2017 | 23 | 0.040 |
Why?
|
| TCF Transcription Factors | 1 | 1997 | 35 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 1998 | 394 | 0.040 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 1997 | 41 | 0.040 |
Why?
|
| Salmonella typhimurium | 2 | 1975 | 70 | 0.040 |
Why?
|
| Alzheimer Disease | 1 | 2005 | 855 | 0.040 |
Why?
|
| Epithelium | 2 | 1997 | 720 | 0.040 |
Why?
|
| Concanavalin A | 1 | 1997 | 67 | 0.040 |
Why?
|
| Sex Distribution | 2 | 2012 | 495 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2019 | 675 | 0.040 |
Why?
|
| False Positive Reactions | 2 | 2010 | 355 | 0.040 |
Why?
|
| Smad4 Protein | 1 | 1998 | 196 | 0.040 |
Why?
|
| Galactose | 1 | 1997 | 87 | 0.040 |
Why?
|
| Prevalence | 2 | 2021 | 3260 | 0.040 |
Why?
|
| Methods | 1 | 1997 | 189 | 0.040 |
Why?
|
| Age Distribution | 2 | 2012 | 698 | 0.040 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 1997 | 35 | 0.040 |
Why?
|
| Endothelium, Vascular | 2 | 2002 | 891 | 0.040 |
Why?
|
| Case-Control Studies | 4 | 2010 | 6100 | 0.040 |
Why?
|
| Genes, Bacterial | 1 | 1998 | 236 | 0.040 |
Why?
|
| Carbohydrate Sequence | 1 | 1996 | 38 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2002 | 573 | 0.040 |
Why?
|
| Combined Modality Therapy | 5 | 2006 | 8865 | 0.040 |
Why?
|
| Azepines | 1 | 2017 | 124 | 0.040 |
Why?
|
| Sialomucins | 1 | 1996 | 3 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 292 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 418 | 0.040 |
Why?
|
| Esophagectomy | 3 | 2006 | 911 | 0.040 |
Why?
|
| Fibrosis | 1 | 2020 | 793 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2015 | 1544 | 0.040 |
Why?
|
| Dietary Fats | 2 | 2010 | 339 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2017 | 626 | 0.030 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1995 | 49 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 2015 | 39 | 0.030 |
Why?
|
| Neoplasm, Residual | 2 | 2016 | 1656 | 0.030 |
Why?
|
| Receptors, Laminin | 1 | 1995 | 13 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2019 | 9180 | 0.030 |
Why?
|
| Monocytes | 1 | 2019 | 788 | 0.030 |
Why?
|
| Decision Trees | 1 | 1996 | 178 | 0.030 |
Why?
|
| Collagen | 1 | 2019 | 752 | 0.030 |
Why?
|
| Pheochromocytoma | 1 | 1998 | 281 | 0.030 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 1975 | 17 | 0.030 |
Why?
|
| Medicare | 1 | 2000 | 860 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1997 | 1037 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2019 | 629 | 0.030 |
Why?
|
| Genes, Regulator | 1 | 1975 | 69 | 0.030 |
Why?
|
| Homosexuality, Male | 1 | 1995 | 71 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 657 | 0.030 |
Why?
|
| Astrocytoma | 1 | 1997 | 321 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 2 | 2006 | 4975 | 0.030 |
Why?
|
| Meningeal Neoplasms | 1 | 1979 | 441 | 0.030 |
Why?
|
| Chemotaxis | 2 | 2002 | 138 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 1995 | 259 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2014 | 23 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 1688 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2012 | 1546 | 0.030 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2014 | 51 | 0.030 |
Why?
|
| Drug Costs | 1 | 1996 | 144 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 3 | 1988 | 769 | 0.030 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2014 | 51 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 342 | 0.030 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 1995 | 168 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 3343 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2014 | 192 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2014 | 181 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2014 | 348 | 0.030 |
Why?
|
| Colectomy | 1 | 2016 | 288 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2015 | 9244 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2004 | 3890 | 0.030 |
Why?
|
| Age Factors | 2 | 2014 | 5377 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2013 | 191 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2018 | 710 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 5159 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2019 | 1529 | 0.030 |
Why?
|
| Vaccination | 1 | 2019 | 1123 | 0.030 |
Why?
|
| Symbiosis | 1 | 2013 | 77 | 0.030 |
Why?
|
| Triazoles | 1 | 2017 | 617 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2012 | 7 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1999 | 1910 | 0.030 |
Why?
|
| Genes, Modifier | 1 | 2012 | 11 | 0.030 |
Why?
|
| Genes, p53 | 1 | 1997 | 1090 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 810 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1999 | 1299 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 702 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 2014 | 335 | 0.030 |
Why?
|
| Hospitals, Special | 1 | 2012 | 24 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2014 | 587 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 1039 | 0.030 |
Why?
|
| Sigmoidoscopes | 1 | 2012 | 2 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2014 | 311 | 0.030 |
Why?
|
| Skin | 1 | 2018 | 1259 | 0.030 |
Why?
|
| Environment | 1 | 2013 | 190 | 0.030 |
Why?
|
| Sex Factors | 2 | 2012 | 2139 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 518 | 0.030 |
Why?
|
| Alleles | 3 | 2006 | 2437 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 1048 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 760 | 0.030 |
Why?
|
| Prednisone | 1 | 1995 | 984 | 0.030 |
Why?
|
| Asia | 1 | 2012 | 142 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 1995 | 875 | 0.030 |
Why?
|
| Nutritional Support | 1 | 2012 | 80 | 0.030 |
Why?
|
| Radiopharmaceuticals | 2 | 2010 | 1301 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2013 | 374 | 0.030 |
Why?
|
| Equipment Contamination | 1 | 2012 | 90 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2013 | 239 | 0.030 |
Why?
|
| Seasons | 1 | 2013 | 340 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2013 | 497 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2014 | 291 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 6942 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 2232 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 4314 | 0.020 |
Why?
|
| Random Allocation | 2 | 1995 | 703 | 0.020 |
Why?
|
| Workload | 1 | 2012 | 198 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 1994 | 583 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 1439 | 0.020 |
Why?
|
| Vincristine | 1 | 1995 | 1511 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2004 | 611 | 0.020 |
Why?
|
| Oncogenes | 1 | 2014 | 673 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2017 | 1987 | 0.020 |
Why?
|
| Keratins | 1 | 1992 | 330 | 0.020 |
Why?
|
| Biological Availability | 1 | 2011 | 214 | 0.020 |
Why?
|
| Serine | 2 | 2004 | 388 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2011 | 91 | 0.020 |
Why?
|
| Wheat Germ Agglutinins | 1 | 1990 | 17 | 0.020 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 1990 | 34 | 0.020 |
Why?
|
| Sialic Acids | 1 | 1990 | 29 | 0.020 |
Why?
|
| Sialyltransferases | 1 | 1990 | 23 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1991 | 682 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 1489 | 0.020 |
Why?
|
| Disposable Equipment | 1 | 2009 | 18 | 0.020 |
Why?
|
| Drug Antagonism | 1 | 2009 | 32 | 0.020 |
Why?
|
| Renin-Angiotensin System | 1 | 2010 | 103 | 0.020 |
Why?
|
| Deoxyglucose | 1 | 2010 | 115 | 0.020 |
Why?
|
| Thiocyanates | 2 | 1988 | 17 | 0.020 |
Why?
|
| Rosaniline Dyes | 1 | 2010 | 108 | 0.020 |
Why?
|
| Fluorescein-5-isothiocyanate | 2 | 1988 | 52 | 0.020 |
Why?
|
| Fluoresceins | 2 | 1988 | 73 | 0.020 |
Why?
|
| Vitamin B 6 | 1 | 2009 | 19 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2006 | 1226 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1990 | 629 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2011 | 553 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2005 | 15862 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 3821 | 0.020 |
Why?
|
| Patient Selection | 1 | 2017 | 2055 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2009 | 1538 | 0.020 |
Why?
|
| Receptors, Mitogen | 1 | 1988 | 13 | 0.020 |
Why?
|
| DNA | 1 | 1997 | 2693 | 0.020 |
Why?
|
| Bacteria | 1 | 2013 | 611 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2011 | 333 | 0.020 |
Why?
|
| Intestines | 1 | 2013 | 686 | 0.020 |
Why?
|
| Preoperative Care | 2 | 2005 | 1529 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 1991 | 1165 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 460 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 4320 | 0.020 |
Why?
|
| Kininogens | 1 | 2008 | 8 | 0.020 |
Why?
|
| Liposomes | 1 | 1990 | 684 | 0.020 |
Why?
|
| Heterozygote | 2 | 2005 | 1020 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 1995 | 1506 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2010 | 272 | 0.020 |
Why?
|
| Glycopeptides | 1 | 2008 | 28 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2008 | 122 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 1990 | 368 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2010 | 205 | 0.020 |
Why?
|
| Suspensions | 1 | 1987 | 17 | 0.020 |
Why?
|
| Video Recording | 1 | 2009 | 267 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 2216 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 1084 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 1995 | 3001 | 0.020 |
Why?
|
| Complement C3 | 1 | 2008 | 78 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 3251 | 0.020 |
Why?
|
| Length of Stay | 1 | 1994 | 1900 | 0.020 |
Why?
|
| Survival Rate | 2 | 2005 | 12221 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 1997 | 5710 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 437 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2008 | 218 | 0.020 |
Why?
|
| Cecum | 1 | 1987 | 42 | 0.020 |
Why?
|
| Observer Variation | 1 | 2009 | 671 | 0.020 |
Why?
|
| Glycemic Index | 1 | 2006 | 29 | 0.020 |
Why?
|
| Cisplatin | 2 | 2004 | 2432 | 0.020 |
Why?
|
| CpG Islands | 1 | 2009 | 633 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1987 | 585 | 0.020 |
Why?
|
| Glioblastoma | 1 | 1997 | 1797 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2009 | 1163 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2012 | 671 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 482 | 0.020 |
Why?
|
| Equipment Design | 1 | 2009 | 1204 | 0.020 |
Why?
|
| Physical Examination | 1 | 1987 | 299 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 1995 | 1763 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 1225 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 551 | 0.020 |
Why?
|
| Nutrition Assessment | 1 | 2006 | 169 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 368 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2008 | 1053 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 1038 | 0.020 |
Why?
|
| Life Tables | 1 | 2004 | 120 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2012 | 1154 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2012 | 1270 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 1323 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 4758 | 0.020 |
Why?
|
| Endoscopy | 1 | 1987 | 479 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2004 | 94 | 0.010 |
Why?
|
| NIH 3T3 Cells | 1 | 2004 | 260 | 0.010 |
Why?
|
| Abdomen | 1 | 2005 | 332 | 0.010 |
Why?
|
| Arachis | 1 | 1984 | 65 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2006 | 333 | 0.010 |
Why?
|
| Digestive System | 1 | 1984 | 114 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 3472 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1984 | 207 | 0.010 |
Why?
|
| DNA Helicases | 1 | 2006 | 434 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2004 | 323 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2006 | 502 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2002 | 115 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2002 | 189 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 644 | 0.010 |
Why?
|
| Fetus | 1 | 1985 | 601 | 0.010 |
Why?
|
| Iron | 1 | 2005 | 376 | 0.010 |
Why?
|
| Carboplatin | 1 | 2004 | 823 | 0.010 |
Why?
|
| Lymphoma | 1 | 2010 | 1467 | 0.010 |
Why?
|
| Mice, SCID | 2 | 1995 | 1869 | 0.010 |
Why?
|
| Radiography | 1 | 2005 | 1904 | 0.010 |
Why?
|
| Binding Sites | 2 | 1999 | 2171 | 0.010 |
Why?
|
| Taxoids | 1 | 2004 | 967 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2004 | 1643 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2016 | 5542 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2013 | 8223 | 0.010 |
Why?
|
| Hemagglutination | 1 | 1999 | 13 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2004 | 848 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 5637 | 0.010 |
Why?
|
| Proteins | 1 | 2008 | 1963 | 0.010 |
Why?
|
| Nucleic Acids | 1 | 1999 | 43 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2004 | 2231 | 0.010 |
Why?
|
| G2 Phase | 1 | 1999 | 206 | 0.010 |
Why?
|
| PC12 Cells | 1 | 1998 | 46 | 0.010 |
Why?
|
| Enzyme Repression | 2 | 1975 | 10 | 0.010 |
Why?
|
| Isoleucine | 2 | 1975 | 29 | 0.010 |
Why?
|
| Biological Transport | 1 | 1999 | 597 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 1996 | 0.010 |
Why?
|
| Valine | 2 | 1975 | 176 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2003 | 899 | 0.010 |
Why?
|
| Mitosis | 1 | 1999 | 615 | 0.010 |
Why?
|
| Leucine | 2 | 1975 | 352 | 0.010 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1995 | 84 | 0.010 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1998 | 262 | 0.010 |
Why?
|
| Chimera | 1 | 1995 | 145 | 0.010 |
Why?
|
| Oxo-Acid-Lyases | 1 | 1974 | 3 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1997 | 641 | 0.010 |
Why?
|
| Hydro-Lyases | 1 | 1974 | 14 | 0.010 |
Why?
|
| Transaminases | 1 | 1974 | 76 | 0.010 |
Why?
|
| RNA, Transfer | 1 | 1974 | 77 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 3719 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 10001 | 0.010 |
Why?
|
| Oxidoreductases | 1 | 1974 | 171 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1997 | 1005 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1995 | 842 | 0.010 |
Why?
|
| Deferoxamine | 1 | 1990 | 28 | 0.010 |
Why?
|
| Indium Radioisotopes | 1 | 1990 | 65 | 0.010 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1990 | 84 | 0.010 |
Why?
|
| Gallium Radioisotopes | 1 | 1990 | 60 | 0.010 |
Why?
|
| Phosphatidylinositols | 1 | 1990 | 60 | 0.010 |
Why?
|
| Bleomycin | 1 | 1990 | 467 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1990 | 660 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1990 | 327 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1988 | 157 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1988 | 185 | 0.010 |
Why?
|
| Butyric Acid | 1 | 1984 | 13 | 0.000 |
Why?
|
| Butyrates | 1 | 1984 | 57 | 0.000 |
Why?
|
| Enzyme Induction | 1 | 1984 | 249 | 0.000 |
Why?
|
| Periodic Acid | 1 | 1974 | 10 | 0.000 |
Why?
|
| Chromatography | 1 | 1974 | 49 | 0.000 |
Why?
|
| Tritium | 1 | 1974 | 200 | 0.000 |
Why?
|
| Cell-Free System | 1 | 1974 | 150 | 0.000 |
Why?
|
| Carbon Radioisotopes | 1 | 1974 | 116 | 0.000 |
Why?
|
| Histidine | 1 | 1974 | 91 | 0.000 |
Why?
|